Tirzepatide
A dual GIP/GLP-1 receptor agonist for diabetes and obesity.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 10, 20, 42, 88, 123.
New guidelines and consensus this year
- Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause SocietyMaturitas2026 Oct
- Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statementCancer2026 Aug 15
- Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)Ann Intern Med2026 Aug
- American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgerySurg Obes Relat Dis2026 Jul
- Swiss obesity clinical practice guidanceSwiss Med Wkly2026 May 19
All papers from the last 12 months
1,392 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medicationsJ Diabetes Metab Disord2026 DecPMID 42871568Review
- GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific riskN Am Spine Soc J2026 DecPMID 42871273Review
- Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetesJ Diabetes Metab Disord2026 DecPMID 42840232
- Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetesObes Pillars2026 DecPMID 42831032
- Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic programAm J Prev Cardiol2026 DecPMID 42828252
- Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysisJ Diabetes Metab Disord2026 DecPMID 42802751
- Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort studyInt J Cardiol2026 Dec 1PMID 42710812
- Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database networkPulmonology2026 DecPMID 42639925
- One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapyAppetite2026 Dec 1PMID 42492687Review
- Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case studyJ Med Econ2026 DecPMID 42021523
More endocrinology trends
All specialties →Next-generation incretin drugs
Triple agonists and amylin combinations such as retatrutide and CagriSema.
Key point: CagriSema led to a greater proportion of adults with obesity achieving BMI and waist-to-height ratio targets than semaglutide, cagrilintide, or placebo.
Oral GLP-1 drugs
Oral semaglutide and small-molecule GLP-1 agonists such as orforglipron.
Key point: In adults with obesity or overweight and type 2 diabetes, once-daily orforglipron reduced bodyweight versus placebo, with safety similar to other GLP-1 agonists.
Automated insulin delivery
Hybrid closed-loop systems that adjust insulin automatically.
Primary aldosteronism
Screening, diagnosis and treatment of primary aldosteronism.
Key point: Universal screening for primary aldosteronism in all patients with hypertension with an aldosterone-to-renin ratio test is now recommended.
Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
tirzepatide[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.